Myelofibrosis: Symptoms, Ruxolitinib, and Transplant Options

Research-informed explainer — last updated April 12, 2026

Myelofibrosis is a bone marrow cancer that replaces normal marrow tissue with scar tissue, impairing blood production and causing a massively enlarged spleen. It is not common — roughly 18,000 Americans are living with it — but it can significantly affect quality of life and in many patients shortens survival. Treatment options have changed materially since the JAK inhibitor ruxolitinib was approved in 2011, and the question of who should be referred for allogeneic stem cell transplant has become more nuanced as new drugs have arrived.

This article explains what myelofibrosis is, what causes it, how symptoms develop, what the evidence shows about ruxolitinib and transplant, and where the field is heading. It draws on research from hematologists at Cleveland Clinic, Mayo Clinic, and Dana-Farber Cancer Institute who have published extensively on myeloproliferative neoplasms and myeloid malignancies.

What is myelofibrosis?

Myelofibrosis (MF) belongs to a family of blood cancers called myeloproliferative neoplasms (MPNs), which also includes polycythemia vera (PV) and essential thrombocythemia (ET). In MF, the bone marrow gradually fills with fibrous scar tissue, reducing its ability to make normal red blood cells, white blood cells, and platelets. Blood-forming activity shifts to the spleen and liver — a process called extramedullary hematopoiesis — causing those organs to enlarge dramatically.

Most cases arise from a somatic mutation in one of three driver genes: JAK2 (in about 60% of patients), CALR (in about 25%), or MPL (in about 7–8%). A small fraction has none of these mutations (triple-negative MF). All three mutations activate JAK-STAT signaling, the same pathway targeted by ruxolitinib.

MF can develop on its own (primary MF) or evolve from PV or ET (secondary MF). Both forms are managed similarly once diagnosed.

Signs and symptoms

Symptoms arise from three main mechanisms: the spleen's enlargement, the bone marrow's failure to produce normal blood cells, and the chronic inflammatory state that accompanies the disease.

Spleen-related symptoms are often the most disabling. The spleen can grow to fill most of the abdomen, causing early satiety (feeling full after a few bites), left-sided abdominal and flank pain, and difficulty with physical activity. In severe cases patients lose significant weight.

Blood count abnormalities include anemia (the most common, causing fatigue, shortness of breath, and lightheadedness), low platelet counts (raising bleeding risk), and variable white cell counts — sometimes elevated early in the disease, sometimes reduced as marrow failure advances.

Constitutional symptoms — severe fatigue, drenching night sweats, fevers, itching (pruritus), and unintended weight loss — are present in a majority of patients. These are driven in large part by elevated inflammatory cytokines, which is one reason JAK inhibitors improve how patients feel even before they produce a spleen response.

How it is diagnosed

Diagnosis requires a bone marrow biopsy confirming fibrosis, along with one or more of the driver mutations (JAK2, CALR, or MPL) and exclusion of other conditions that cause marrow fibrosis. The WHO classification criteria for myeloid neoplasms provide the diagnostic framework, which has been revised to incorporate molecular findings [4].

Blood tests at diagnosis include a complete blood count, peripheral blood smear, and molecular testing for driver mutations. Additional mutation testing — ASXL1, EZH2, IDH1/IDH2, and others — helps identify patients at higher risk of accelerated disease or transformation to acute leukemia. Work defining how somatic mutations in specific genes predict the ontology and behavior of myeloid malignancies [8] informs why this molecular profiling matters in MF.

Risk stratification uses scoring systems such as DIPSS (Dynamic International Prognostic Scoring System) or more recently MIPSS70 and MYSEC-PM, which incorporate molecular data. These scores estimate median survival and help guide decisions about whether and when to consider transplant.

Treatment options

Ruxolitinib (JAK inhibitor)

Ruxolitinib is an oral inhibitor of JAK1 and JAK2 — the kinases that are constitutively activated by JAK2 V617F and related mutations. It was the first targeted therapy approved for myelofibrosis and remains the primary treatment for most symptomatic patients.

The COMFORT-II trial, a phase 3 study comparing ruxolitinib to best available therapy in intermediate- and high-risk MF, showed that 28% of ruxolitinib-treated patients achieved a 35% or greater reduction in spleen volume at week 48, compared to none in the best available therapy arm. Maintaining spleen response over time was meaningful — nearly half of patients who responded were still maintaining that response at five years. A trend toward improved overall survival was observed, though the trial was not powered to show a statistically significant mortality benefit definitively.

The COMFORT-I trial compared ruxolitinib to placebo and showed significant spleen responses and symptom improvements. Long-term follow-up data at five years continued to show a survival advantage for patients originally assigned to ruxolitinib.

Ruxolitinib works regardless of whether JAK2, CALR, or MPL mutation is present — consistent with the understanding that all three activate the same JAK pathway. The analogy to kinase inhibitors in other myeloid diseases is instructive: imatinib's mechanism in eosinophilic disorders driven by PDGFRA-FIP1L1 fusion [7] demonstrates how targeting the specific kinase driving a myeloid malignancy can produce durable responses, and the same logic underlies ruxolitinib in MF. Similarly, precision targeting of enzyme mutations in related myeloid diseases — such as IDH2 inhibition in AML [8] — informs how molecularly driven therapy can reshape myeloid cancer management broadly.

The main side effects of ruxolitinib are anemia and thrombocytopenia (low platelets), which require dose adjustments in some patients. Infection risk is elevated, and the drug suppresses immune function. When ruxolitinib is stopped abruptly, symptoms can rebound rapidly — dose tapering is preferred.

When transplant is considered

Allogeneic stem cell transplant is the only potentially curative treatment for myelofibrosis. It replaces the patient's diseased bone marrow with healthy donor marrow and can produce long-term disease control in a fraction of patients. But it carries substantial risk of treatment-related complications and mortality, which means it is not appropriate for all patients.

Current guidelines suggest considering transplant for intermediate-2 and high-risk patients who are fit enough to tolerate the procedure — generally younger patients without major comorbidities, though reduced-intensity conditioning regimens have expanded eligibility to patients in their 60s and even carefully selected patients in their 70s.

The decision is complex. JAK inhibitors like ruxolitinib can reduce spleen size before transplant, potentially improving the procedure's outcome, but prolonged ruxolitinib therapy does not reduce the risk of leukemic transformation. Patients at high risk based on molecular features — particularly those with ASXL1 mutations or more than one high-risk mutation — tend to be considered for transplant referral sooner.

Risk stratification frameworks that integrate molecular data help identify patients most likely to transform to acute leukemia without intervention, analogous to how GATA2 mutation analysis in myelodysplastic syndromes identifies pediatric patients at highest risk of progression [4].

Second-line and newer agents

When ruxolitinib loses effectiveness — either because of disease progression or intolerance — several other JAK inhibitors are available:

Fedratinib is approved for intermediate- or high-risk primary or secondary MF, including in patients who have been previously treated with ruxolitinib.

Pacritinib is approved specifically for patients with low platelet counts (below 50,000), where ruxolitinib cannot be used or must be stopped due to thrombocytopenia. It has a selectivity profile that allows use in this difficult subpopulation.

Momelotinib is approved for symptomatic and anemia-associated MF and has shown evidence of improving hemoglobin and reducing transfusion dependence — addressing a significant gap, since anemia is often the most debilitating problem in later-stage disease.

For patients with AL amyloidosis or related plasma cell disorders presenting alongside myeloid disease, establishing standardized criteria for organ involvement and response [6] allows hematologists to assess the full burden of disease across overlapping conditions.

What specialists are discovering

Research interest in myelofibrosis is focused on two areas. First, combinations of ruxolitinib with agents that target other pathways activated in MF — including BET inhibitors, telomerase inhibitors (imetelstat), and BCL-2 inhibitors — are in clinical trials. Second, understanding which patients are most likely to benefit from early versus delayed transplant, and how pre-transplant treatment with JAK inhibitors affects transplant outcomes.

Somatic mutation profiling at diagnosis is becoming more routine, with evidence that higher-risk molecular signatures predict faster progression to blast phase and shorter survival. Identifying patients in those high-risk groups earlier allows for timely transplant referral — while they are still fit enough to tolerate it.

Work on immune-mediated myeloid diseases, including the role of dysregulated STAT signaling pathways in clonal myeloid disorders [2], continues to inform mechanistic understanding of how abnormal cytokine signaling sustains myelofibrosis and related MPNs. The complement pathway findings that validated targeted inhibition in PNH [1][3][5] provide a parallel example of how identifying a single pathogenic mechanism can lead to transformative therapy — a model the MF field is attempting to replicate.

Questions to ask your doctor

• What is my risk category (low, intermediate-1, intermediate-2, or high) based on my scores and molecular findings?
• Do I have any high-risk mutations (ASXL1, EZH2, IDH1/IDH2) that would suggest I should be referred for transplant evaluation sooner?
• Should I start ruxolitinib now, and what spleen and symptom response would you expect?
• If I need a transplant, when should we start that evaluation? Is there a time window when I would be most likely to benefit?
• If ruxolitinib stops working or causes significant anemia, what would the next step be?
• Am I a candidate for any clinical trials combining ruxolitinib with other agents?

The bottom line

Myelofibrosis is a serious bone marrow cancer, but it is not untreatable. Ruxolitinib provides meaningful spleen reduction and symptom relief for most intermediate- and high-risk patients and has demonstrated a survival benefit in long-term follow-up. Allogeneic transplant remains the only potentially curative option and should be considered earlier in patients with high-risk molecular features.

The newer JAK inhibitors — fedratinib, pacritinib, and momelotinib — have expanded options for patients who cannot tolerate or no longer respond to ruxolitinib. The right sequence and combination depend on the patient's risk score, molecular profile, transfusion needs, and fitness for transplant. This is a disease where seeing a specialist at a center that treats significant volumes of MPN patients makes a real difference in decision-making.